Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598306 · ClinicalTrials.gov registry record · Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06598306: Recruiting Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.
NCT06598306 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 220 participants, above the 167-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598306, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Conditions Studied
Interventions
- DRUG Tarlatamab
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - Ghent
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
- Centre Hospitalier Universitaire de Liege - Sart Tilman - Liège
- Universitaetsklinikum Regensburg - Regensburg
- Universitaetsklinikum Wuerzburg - Würzburg
- Wakayama Medical University Hospital - Wakayama
- Uniwersyteckie Centrum Kliniczne - Gdansk
- Instytut Centrum Zdrowia Matki Polki - Lodz
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu - Przemyśl
New South Wales
- Chris OBrien Lifehouse - Camperdown
- Calvary Mater Newcastle Hospital - Waratah
California
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
Illinois
- University of Illinois Chicago - Chicago
Michigan
- Trinity Health Saint Joseph Mercy Ann Arbor - Ann Arbor
South Dakota
- Avera Cancer Institute - Sioux Falls
Texas
- University of Texas MD Anderson Cancer Center - Houston
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2030-03-27 |
| Phase | Phase 1 |
What NCT06598306 shows while recruiting
NCT06598306 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 167-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.
NCT06598306 names 20 study sites across 11 states, led by Other, New South Wales, California.
Frequently Asked Questions
What is clinical trial NCT06598306 about?
NCT06598306 is a clinical study titled "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)". The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
What is the current status of trial NCT06598306?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-10-07. Estimated completion is 2030-03-27.
What conditions does trial NCT06598306 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT06598306?
The interventions under investigation include: Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT06598306?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598306 being conducted?
This trial has 20 study locations across California, Illinois, Michigan, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598306's enrollment target sits among peer trials
220 7th of 25 higher than 19 of 25 other Extensive-stage Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
-
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
RECRUITING · Phase 1
-
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
RECRUITING · Phase 1
-
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
ACTIVE NOT RECRUITING · Phase 1
-
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI